Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03495921 · ClinicalTrials.gov registry record · Phase 3
A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide
A Phase 3 study, sponsored by Gradalis.
- Terminated
- Registry status
- Phase 3
- Development phase
- 32
- Enrollment target
NCT03495921 is a Phase 3 study that was terminated before completion, run by Gradalis. The registered enrollment target is 32 participants.
The verdict
NCT03495921, a Phase 3 study, was terminated before completion, sponsored by Gradalis.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 32 participants
- Enrollment target
Study Summary
The goal of this clinical trial was to compare participants with first relapse or refractory Ewing's sarcoma when treated with investigational product (Vigil) in addition to the standard treatment of irinotecan and temozolomide compared to the standard treatment of irinotecan and temozolomide alone. The main question it aimed to answer is "Will participants who receive Vigil in addition to irinotecan and temozolomide have a prolonged time to progression and improved quality of life compared to the participants who receive irinotecan and temozolomide alone?".
Interventions
- DRUG Temozolomide
- DRUG Irinotecan
- BIOLOGICAL Vigil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2018-08-21 |
| Est. Completion | 2022-01-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03495921
The ClinicalTrials.gov registry entry for NCT03495921 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gradalis, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Temozolomide is the first listed.
NCT03495921 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03495921 about?
NCT03495921 is a clinical study titled "A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide". The goal of this clinical trial was to compare participants with first relapse or refractory Ewing's sarcoma when treated with investigational product (Vigil) in addition to the standard treatment of irinotecan and temozolomide compared to the standard treatment of irinotecan and temozolomide alone....
What is the current status of trial NCT03495921?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 32 participants. The study started on 2018-08-21. Estimated completion is 2022-01-20.
What interventions are being tested in trial NCT03495921?
The interventions under investigation include: Temozolomide (DRUG), Irinotecan (DRUG), Vigil (BIOLOGICAL).
Who is sponsoring clinical trial NCT03495921?
This trial is sponsored by Gradalis, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.